Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide effects on postprandial chylomicron and VLDL metabolism in type 2 diabetes
2013-005075-40Phase 4Completed
- Sponsor
- University of Helsinki
- Start
- Feb 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by University of Helsinki. Primary endpoint: Effect of liraglutide on chylomicron triglyceride and apoB48 kinetics. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-005075-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005075-40.